Nanoparticles loaded with bee venom kill HIV
(Medical Xpress)—Nanoparticles carrying a toxin found in bee venom can destroy human immunodeficiency virus (HIV) while leaving surrounding cells unharmed, researchers at Washington University School of ...
HIV & AIDS
Mar 08, 2013 |
5 / 5 (29) |
3
|
Daily HIV prevention approaches didn't work for African women in the VOICE study
Results of a major HIV prevention trial suggest that daily use of a product – whether a vaginal gel or an oral tablet – does not appear to be the right approach for preventing HIV in young, unmarried African women.
HIV & AIDS
Mar 04, 2013 |
not rated yet |
0
Tenofovir Gel wins out in drug absorption study, but HIV prevention trials say differently
A novel head-to-head study looking at differences in how the antiretroviral (ARV) drug tenofovir gets absorbed in the body as either an oral tablet or a vaginal gel found tenofovir gel can achieve substantially higher concentrations ...
HIV & AIDS
Jan 30, 2013 |
not rated yet |
0
Novel intravaginal ring shows promise in HIV prevention
A new 90-day intravaginal ring has been developed—that for the first time—enables the long-lasting vaginal delivery of tenofovir (TFV), the only topical prophylactic shown to be effective at reducing the sexual transmission ...
HIV & AIDS
Oct 16, 2012 |
not rated yet |
0
Reduced glycerin formulation of tenofovir vaginal gel safe for rectal use
A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests a study published online this week in the Journal of Antimicrobial Chemotherapy. In lab ...
HIV & AIDS
May 17, 2012 |
5 / 5 (1) |
0
Will women use microbicides to protect themselves against HIV?
Are women willing to use a vaginal gel to protect themselves against HIV infection? Researchers at The Miriam Hospital say that is the million dollar question when it comes to developing products known as microbicides that ...
HIV & AIDS
Apr 19, 2012 |
5 / 5 (1) |
0
Rectal formulation of tenofovir gel safe and acceptable in early phase clinical study
A gel formulation of the antiretroviral drug tenofovir designed specifically for rectal use was found safe and acceptable, according to a Phase I clinical study led by the U.S. National Institutes of Health (NIH)-funded Microbicide ...
HIV & AIDS
Mar 06, 2012 |
not rated yet |
0
NIH discontinues tenofovir vaginal gel in 'VOICE' HIV prevention study
A large-scale clinical trial evaluating whether daily use of an antiretroviral-containing oral tablet or vaginal gel can prevent HIV infection in women is being modified because an interim review found that the gel, an investigational ...
HIV & AIDS
Nov 28, 2011 |
not rated yet |
0
HIV trial scrapped after gel found to be ineffective
In a major setback for AIDS prevention research, a clinical trial of a new vaginal gel supposed to reduce HIV infections has been suspended after studies showed it to be ineffective.
HIV & AIDS
Nov 27, 2011 |
not rated yet |
2
Double duty: Anti-HIV topical gel also protects against herpes virus
HIV infection is commonly associated with other sexual infections, such as herpes simplex virus (HSV). Infection with HSV facilitates the risk of HIV infection and negatively impacts the clinical course of HIV disease. Therefore, ...
HIV & AIDS
Oct 19, 2011 |
3.7 / 5 (3) |
0
NIH modifies 'VOICE' HIV prevention study in women
A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study ...
HIV & AIDS
Sep 28, 2011 |
not rated yet |
0
Anti-HIV gel being evaluated in pregnant and breastfeeding women
Determining whether a promising HIV prevention gel is safe for women to use while they are pregnant or breastfeeding is the aim of a new clinical trial being conducted by the National Institutes of Health-funded Microbicide ...
HIV & AIDS
Jun 20, 2011 |
not rated yet |
0
